Eupraxia Reports Positive EoEHSS Sub-Score Data in Phase 1b/2a RESOLVE Trial
Event summary
- Eupraxia Pharmaceuticals released EoEHSS sub-score data from its ongoing Phase 1b/2a RESOLVE trial for eosinophilic esophagitis (EoE) at Digestive Disease Week.
- EoEHSS sub-scores for inflammation showed improvements across all cohorts at 12 and 36 weeks.
- EoEHSS sub-scores for tissue architecture (fibrosis) improved in most cohorts at 12 and 36 weeks.
- The highest dose cohort (Cohort 9) demonstrated the largest improvements, with over 90% improvement in inflammation and over 83% in fibrosis.
The big picture
Eupraxia's positive EoEHSS sub-score data from the RESOLVE trial highlights the potential of its Diffusphere technology to deliver targeted, extended-release treatments for EoE. The results suggest a significant step forward in addressing the unmet medical need in EoE, a disease affecting over 450,000 people in the U.S. The strategic focus on local, controlled drug delivery could position Eupraxia as a key player in the inflammatory gastrointestinal disease space.
What we're watching
- Clinical Efficacy
- How sustained improvements in EoEHSS sub-scores will impact the Phase 2b portion of the RESOLVE trial.
- Dose Optimization
- Whether the highest dose (Cohort 9) will be the focus of future trials and regulatory filings.
- Market Differentiation
- The pace at which Eupraxia can position EP-104GI as a differentiated treatment for EoE.
Related topics